Evidence map›Paper›PMID 38573183›Full record

ArticleFuture oncology (London, England)2024

Preclinical and phase I studies of an antisense oligonucleotide drug targeting

Yonggang Li, Zhe Xu, Yuanyuan Li, Tianjun Jiang, Fanping Meng, Junliang Fu, Lei Huang, Fengchao Wang, Xia Wang, Fusheng Wang

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yonggang LiSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Zhe XuSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.ORCID 0000-0002-3338-4229
Yuanyuan LiSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Tianjun JiangSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Fanping MengSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Junliang FuSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Lei HuangSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
Fengchao WangYoucare Pharmaceutical Group Co Ltd, Beijing, 100176, China.
Xia WangYoucare Pharmaceutical Group Co Ltd, Beijing, 100176, China.
Fusheng WangSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.ORCID 0000-0002-8043-6685
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Liver NeoplasmsMaximum Tolerated DoseOligonucleotides, AntisenseReceptor, IGF Type 1AdultAgedAnimalsAntineoplastic AgentsDrug Evaluation, PreclinicalFemaleHumansMacaca mulattaMaleMiddle AgedMolecular Targeted TherapyRatsAntineoplastic AgentsIGF1R protein, humanOligonucleotides, AntisenseReceptor, IGF Type 1antisense oligonucleotideCT102IGF-1Rliver cancerpharmacokineticstargeted therapy

Identifiers

PMID38573183
PMCPMC11534120
OpenAlexW4393950082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.